Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 465

The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.

IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy

Open access
Travis, William D., Dacic, Sanja, Wistuba, Ignacio, Sholl, Lynette, Adusumilli, Prasad, Bubendorf, Lukas, Bunn, Paul, Cascone, Tina, Chaft, Jamie, Chen, Gang, Chou, Teh-Ying, Cooper, Wendy, Erasmus, Jeremy J., Ferreira, Carlos Gil, Goo, Jin-Mo, Heymach, John, Hirsch, Fred R., Horinouchi, Hidehito, Kerr, Keith, Kris, Mark, Jain, Deepali, Kim, Young T., Lopez-Rios, Fernando, Lu, Shun, Mitsudomi, Tetsuya, Moreira, Andre, Motoi, Noriko, Nicholson, Andrew G., Oliveira, Ricardo, Papotti, Mauro, Pastorino, Ugo, Paz-Ares, Luis, Pelosi, Giuseppe, Poleri, Claudia, Provencio, Mariano, Roden, Anja C., Scagliotti, Giorgio, Swisher, Stephen G., Thunnissen, Erik, Tsao, Ming S., Vansteenkiste, Johan, Weder, Walter, Yatabe, Yasushi·2020·Journal of Thoracic Oncology

Abstract

Currently there is no established guidance on how to process and evaluate resected lung cancer specimens following neoadjuvant therapy in the setting of clinical trials and clinical practice. There is also a lack of precise definitions on the degree of pathologic response, including major pathologic response (MPR) or complete pathologic response (CPR). In other cancers such as osteosarcoma, colorectal, breast and esophageal carcinomas, there have been multiple studies investigating pathologic assessment of the effects of neoadjuvant therapy including some detailed recommendations on how to handle these specimens. A comprehensive mapping approach to gross and histologic processing of osteosarcomas following induction therapy has been used for over 40 years. The purpose of this article is to outline detailed recommendations on how to process lung cancer resection specimens and to define pathologic response including MPR and CPR following neoadjuvant therapy. A standardized approach is recommended to assess the percentages of: 1) viable tumor, 2) necrosis and 3) stroma (including inflammation and fibrosis) with a total adding up to 100%. This is recommended for all systemic therapies including chemotherapy, chemoradiation, molecular targeted therapy, immunotherapy or any future novel therapies yet to be discovered whether administered alone or in combination. Specific issues may differ for certain therapies such as immunotherapy, but the grossing process should be similar and the histologic evaluation should contain these basic elements. Standard pathologic response assessment should allow for comparisons between different therapies and correlations with disease free survival and overall survival in ongoing and future trials. The International Association for the Study of Lung Cancer (IASLC) has an effort to collect such data from existing and future clinical trials. These recommendations are intended as guidance for clinical trials, although it is hoped they can be viewed as suggestion for good clinical practice outside of clinical trials, to improve consistency of pathologic assessment of treatment response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2020.01.005

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 77 references

Cited by

See all 465

Metadata

Authors
Travis, W. D., Dacic, S., Wistuba, I., Sholl, L., Adusumilli, P., Bubendorf, L., Bunn, P., Cascone, T., Chaft, J., Chen, G., Chou, T.-Y., Cooper, W., Erasmus, J. J., Ferreira, C. G., Goo, J.-M., Heymach, J., Hirsch, F. R., Horinouchi, H., Kerr, K., Kris, M., Jain, D., Kim, Y. T., Lopez-Rios, F., Lu, S., Mitsudomi, T., Moreira, A., Motoi, N., Nicholson, A. G., Oliveira, R., Papotti, M., Pastorino, U., Paz-Ares, L., Pelosi, G., Poleri, C., Provencio, M., Roden, A. C., Scagliotti, G., Swisher, S. G., Thunnissen, E., Tsao, M. S., Vansteenkiste, J., Weder, W., & Yatabe, Y.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2020-05
Volume
15
Issue
5
Pages
709-740
ISSN
1556-0864 (ISSN-L)
OpenAlex
W3003197494
Cited by
465
References
77
FWCI
26.72
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. https://app.cochat.ai/papers/10.1016/j.jtho.2020.01.005
The paper
Travis, W. D., Dacic, S., Wistuba, I., Sholl, L., Adusumilli, P., Bubendorf, L., Bunn, P., Cascone, T., Chaft, J., Chen, G., Chou, T.-Y., Cooper, W., Erasmus, J. J., Ferreira, C. G., Goo, J.-M., Heymach, J., Hirsch, F. R., Horinouchi, H., Kerr, K., . . . Yatabe, Y. (2020). IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2020.01.005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.